Myovant Sciences and Pfizer Receive U.S. FDA Approval of
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a...
Source: globenewswire.com
Sensitive Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sensitive Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sensitive Malignancies Today - Breaking & Trending Today
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
06.08.2022 - Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment ...
Source: wallstreet-online.de
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
Myovant Sciences and Pfizer Provide Update on Supplemental
BASEL, Switzerland and NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced today an update on the...
Source: globenewswire.com
Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
/PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and...
Source: prnewswire.com